Latest signal
last curated pass Oct 6, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets
Recent curated signals
N=1 test The altitude arc gets an unplanned coda: a self-injuring night terror attributed to five days at 7,000 ft plus missed bedtimes The October 4 “order has been restored” epilogue acquired a footnote two nights later: Johnson reported a night terror — “throwing myself off the bed and bloodying up my back, sides and arms” after dreaming of jumping off a runaway train — a recurrence of a past problem he says once put him in the hospital. His mechanism section is accurate against sleep medicine: night terrors are non-REM disorders of arousal arising from deep slow-wave (stage N3) sleep in the first third of the night — his “1-3 hours after sleep onset” matches the documented one-to-three-hour window — REM’s muscle atonia is why ordinary nightmares are not acted out, and sleep deprivation is a documented precipitant. His causal attribution (five days at 7,000 ft while missing bedtimes for consecutive social events) is consistent with the September 29–30 wearable-dip/rebound arc and with acclimatization timelines of several weeks. The boundaries: this is a self-diagnosed, unmonitored account — no polysomnography, no clinician named, and the “research” he did is uncited — and adult night terrors with self-injury are a presentation sleep medicine associates with underlying conditions worth clinical evaluation. The dashboard records an attributed N=1 event narrative with verified mechanism context—not evidence that altitude travel causes night terrors, a sleep-safety guideline, or medical advice. 3 sourcesSleep / parasomnia / altitude recovery Female health Quote-posting Tolo’s female-health thread: the Ambien claim that verifies nearly verbatim against the FDA label Johnson quote-posted the zolpidem fact from Kate Tolo’s five-fact female-health thread: “Studies found that women had around 45% higher blood concentrations of ambien (zolpidem) than men after the same dose. Women also cleared the drug from the bloodstream more slowly.” This one is about as checkable as feed claims get: the FDA Ambien label’s “Gender Difference in Pharmacokinetics” section states that Cmax and AUC were “approximately 45% higher at the same dose in female subjects compared with male subjects” because “women clear zolpidem tartrate from the body at a lower rate than men,” and the FDA’s January 2013 safety communication halved the recommended bedtime dose for women (10 mg to 5 mg immediate-release; 12.5 mg to 6.25 mg extended-release) on next-morning-impairment data. The quoted claim is, in effect, the label. The boundaries: the post is a quote-post amplification rather than new analysis, it names no source itself (the figures belong to the FDA documents), and zolpidem is a Schedule IV prescription hypnotic whose dosing is a clinician decision. The dashboard records an attributed female-health claim with verified regulatory provenance—not a dosing directive, a medication change without a prescriber, or medical advice. 4 sourcesSex-specific pharmacokinetics / female-health claims Research claim “The male body by age 50”: five decline figures and a weekly counter-protocol, three of five verifiable Johnson’s highest-engagement post in weeks (5.6k likes) lists five decline figures — testosterone down 30%, arterial stiffness up 30%, bone density down 10%, muscle mass down 10%, prostate enlargement in 50% of men — against a weekly counter-protocol: 4 hr heavy lifting, 3 hr zone 2, 45 min HIIT, 2 hr sauna, 8 hr/night sleep. Three of the five figures verify against named literatures: the testosterone figure tracks the Massachusetts Male Aging Study’s longitudinal total-testosterone decline of about 1.6%/yr (compounding to roughly −28% from peak by 50, with free/bioavailable testosterone falling faster at 2–3%/yr; the Baltimore Longitudinal Study found the same direction); the muscle figure matches cross-sectional medians of about 4.7% of peak mass per decade in men (≈10% from 30 to 50); and the prostate figure matches Berry et al.’s classic autopsy series exactly — 50% of men show pathological benign prostatic hyperplasia at ages 51–60. The arterial-stiffness and bone-density percentages name no source and are recorded as attributed values, and the prescription is Johnson’s own weekly stack, not a clinical recommendation — no volume in it is an individually optimized dose, and the post cites no trial of the combined stack. The dashboard records an attributed claims-plus-protocol post with verified context for three figures—not a diagnosis, a male-aging checklist, or medical advice. 5 sourcesMale aging / exercise and sauna prescription Algorithmic health The readout arrives: Lütke’s race physiology reviewed — 171 bpm peak, 4.6% body mass lost, 41 breaths/min — but still no blood panel The October 2 “reviewing Tobi’s performance via biomarkers” announcement produced its narrative readout. Johnson reconstructed Lütke’s 2.5-hour Petit Le Mans stint physiologically — heart rate peaking at 171 bpm and already at 136 bpm thirty minutes before the race, qualifying laps faster as heart rate rose, 4.6% of body mass lost to sweat, breathing averaging 41 breaths/min on flying laps (93 liters/min, peaking at 59) — closing with performance context (fastest race lap on lap 88 at 1:15.359, over two hours in; +2.60% off class best against world-class professionals; 150 drivers) and a flow-state neuroscience frame: downregulated prefrontal self-monitoring, norepinephrine-driven time dilation, and the same one-brain-region-vs-fifteen compression the October 3 post used. The one checkable side-claim verifies with a caveat: “at 2% dehydration your reaction time measurably decreases” matches the direction of the Wittbrodt & Millard-Stafford meta-analysis (Med Sci Sports Exerc, 2018: cognitive impairment greater beyond 2% body-mass loss), but that analysis found reaction-time-specific effects nonsignificant (ES −0.10) — attention, executive function, and motor coordination are the impaired domains. The structural boundary is unchanged: the announced “deep molecular profiling” blood draws still have no panel, method, or result — this readout is wearable-and-telemetry narrative, not the molecular data, and whether the pre/post blood comparison yields anything remains unpublished. The dashboard records an attributed readout narrative with verified hydration-literature context—not evidence that biomarker review improves driving performance, a hydration strategy, or medical advice. 4 sourcesMethod export / motorsport physiology Algorithmic health Ten days on the road end at home: “Order has been restored,” five-hour morning routine resumed “going all out” The road trip this dashboard has tracked since September 29 ended at home, and the closing post is the arc’s only unquantified one: “I’m back home after 10 days on the road. Just completed my five hour morning routine, going all out. I crave the discomfort. It’s my happy place. Find it miserable to live without. Order has been restored.” The count is internally consistent with the tracked window: the five-day altitude leg that ended with the September 29 “back at sea level” post implies departure around September 24–25, Petit Le Mans ran October 2–3, and September 25 through October 4 is ten days inclusive. The discomfort framing extends the August 16 discipline-as-mastery self-description into open identity language (“miserable to live without”), and unlike every other post in the arc it attaches no measurement—no wearable index, no biomarker panel, no outcome claim. The dashboard records an attributed behavior and identity statement closing a measured arc—not evidence that the five-hour routine produces its claimed benefits, a reader routine, or medical advice. 3 sourcesRoutine adherence / behavior Algorithmic health The racing experiment runs: Johnson collects Lütke’s blood “before and after his 2.5 hr race,” calling it a first-in-world deep molecular profile On race day the announced experiment acquired data. At 15:10 UTC Johnson posted the physiological case for the weekend—Lütke driving “over 180 mph,” up to 4.2 g throwing his body forward with “715 lbs of force” and his head by “67 lbs,” braking requiring “up to 200 lbs of leg force,” a cockpit averaging “104-122°F,” core temperature reaching “102°F,” heart rate “140-170 bpm,” and up to “170 fl oz (5 kg)” of sweat and “11 lbs” of body-weight loss in a car with no driver cooling—then at 22:02 UTC closed the arc October 2 left open: “We completed a first-in-world racing experiment. I collected Tobi’s blood before and after his 2.5 hr race. This blood test is unique. It’s deep molecular profiling. What happens to the body under these extreme conditions?” The internal arithmetic is self-consistent (4.2 g on a ~170 lb driver ≈ 714 lb; 4.2 g on a ~16 lb head ≈ 67 lb; 5 kg of sweat ≈ 11 lb), and the physiology targets are literature-adjacent: measured endurance racing shows cockpits of ~40–50°C, heart rates of 159–170 bpm sustained for full stints, and sweat rates around 0.6 L/h with clinically meaningful dehydration over longer events (Carlson et al., J Strength Cond Res, 10.1519/JSC.0000000000002268). The boundaries: the headline numbers are Johnson’s own with no per-race telemetry source; the 5 kg sweat claim implies ~2 L/h for 2.5 hours—roughly triple the ~0.6 L/h typical of measured driver studies and a level literature associates with extreme conditions; and “deep molecular profiling” names no panel, analyzer, or method, so what was measured, when, and how it will be analyzed remain unstated. The dashboard records an attributed experiment narrative with verified context—not evidence that molecular profiling of drivers is novel or useful, a hydration or cooling protocol, or medical advice. 4 sourcesMethod export / motorsport physiology Research claims “Car racing is cognitive enhancement”: three research claims compressing NeuroRacer and driver-neuroscience findings An hour before the race, Johnson posted a three-claim case that racing itself is cognitive enhancement: “12 hrs on a driving video game, and 60-85 yr olds were cognitively overtaking 20 yr olds”; “race car drivers do in one brain region what a novice does in 15”; and “six months later, the seniors kept the gains with zero practice.” Two of the three anchor to real studies with the numbers matching closely. The first and third trace to Anguera et al. (Nature, 2013, 10.1038/nature12486): 12 hours of adaptive multitasking training on the NeuroRacer 3-D driving game over a month left 60–85-year-olds with multitasking costs better than untrained 20-year-olds’ single-session performance (−16.2% vs −36.7% cost), with gains persisting six months without booster sessions. The second traces to neural-efficiency work in actual drivers: Bernardi et al. (PLoS ONE, 2013, 10.1371/journal.pone.0077764) found professional racing drivers recruit a smaller volume of task-related regions than naïve drivers, and the follow-up structural study (Frontiers Hum Neurosci, 2014, 10.3389/fnhum.2014.00888) found pros more consistently recruiting motor-control and spatial-navigation areas with retrosplenial-cortex gray-matter density correlating with racing success. The boundaries: no study Johnson cites shows actual race-car driving enhancing cognition in drivers—the evidence runs from a custom video game in older adults and cross-sectional expert/novice comparisons, the latter unable to separate training from selection; “one brain region vs 15” is a compression, not a measured count; and the 6-month retention figure is from the game study’s older adults, not from any racing population. The dashboard records an attributed research-claims post with verified sources—not evidence that racing is a cognitive-enhancement intervention, a brain-training recommendation, or medical advice. 4 sourcesCognitive enhancement / driving expertise neuroscience Algorithmic health Algorithmic health goes to the race track: Johnson reviews a friend’s qualifying stint via “car stats, micro decisions, blood biomarkers” Johnson posted from the Motul Petit Le Mans weekend at Michelin Raceway Road Atlanta, where three friends—Shopify founder Tobi Lütke, Ruby on Rails creator DHH (David Heinemeier Hansson), and Le Mans podium finisher Mathias Beche—share the No. 11 TDS Racing ORECA LMP2 07 in the 10-hour IMSA season finale. The entry verifies against IMSA’s official entry list (54 cars, 2.54-mile 12-turn road course, green flag October 3, 12:10 p.m. ET), and both résumés check out: DHH won the GTE-Am class at the 2014 24 Hours of Le Mans with Aston Martin Racing, and Beche is a former ELMS LMP2 champion and 2014 Le Mans LMP1-L class winner with Rebellion Racing. The dashboard-relevant move is the second post: after Lütke “just got off the track” from qualifying, Johnson said he is now “reviewing Tobi’s performance via biomarkers”—“the car stats + his micro decisions + his blood biomarkers”—the algorithmic-health loop (telemetry, decisions, blood) applied to another person’s performance domain. The physiology framing is broadly literature-consistent: endurance racing measured in studies shows cockpit temperatures of roughly 40–50°C in multi-layer fireproof suits, heart rates of 159–170 bpm sustained for full stints (up to ~89% of age-predicted maximum), sweat rates around 0.6 L/h with clinically meaningful dehydration in longer races, and research protocols that themselves use ingestible core-temperature pills and continuous glucose monitors in driver-athletes (Carlson et al., J Strength Cond Res 2018; Frontiers Sports Act Living 2025). The boundaries: the headline “11 lbs of body weight” loss, “122°F cockpit,” “170 heart rate,” “4.2 g,” and “600–900 calories per hour” figures are Johnson’s own numbers with no per-race source; the biomarker review of Lütke is announced, not published—no panel, method, or result exists; and whether blood biomarkers add anything to established driver-science monitoring is untested. The dashboard records an attributed method-export and event narrative with verified racing context—not evidence that biomarker review improves driving performance, a training or hydration protocol, or medical advice. 6 sourcesMethod export / motorsport physiology
// Reference paths
Move from feed to dossiers
Each route keeps source trails and medical caution visible. Protocol Health
Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.
Protocol LongevityHabits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.
Protocol NutritionHabits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.
Protocol SleepHabits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.
Reference Concepts39 source-aware glossary entries, including concepts without dedicated wiki pages yet.
entity BlueprintBlueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer
concept Blueprint ProtocolThe Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a
concept Don't DieDon't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a
concept Biomarker-driven longevity protocolsA biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre
Signal MetricsInspect source velocity by range, content type, and fallback API state.